Vistagen Therapeutics, Inc.
VTGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001411685
No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Vistagen Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 116
- +10 vs. Q4 2021
- Shares held
- 135.4M
- −2.80M (−2.0%) vs. Q4 2021
- Total value
- $167.8M
- −$101.4M (−37.7%) vs. Q4 2021
- New holders
- 19
- 30 more added
- Sold out
- 9
- 39 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VTGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 48 | $2.54M |
| Q1 2026 | 56 | $8.12M |
| Q4 2025 | 55 | $8.84M |
| Q3 2025 | 58 | $81.8M |
| Q2 2025 | 51 | $30.3M |
| Q1 2025 | 48 | $39.0M |
| Q4 2024 | 54 | $44.9M |
| Q3 2024 | 47 | $45.3M |
| Q2 2024 | 43 | $56.3M |
| Q1 2024 | 42 | $90.8M |
| Q4 2023 | 46 | $90.0M |
| Q3 2023 | 34 | $15.7M |
| Q2 2023 | 33 | $1.82M |
| Q1 2023 | 83 | $4.79M |
| Q4 2022 | 86 | $4.15M |
| Q3 2022 | 93 | $9.13M |
| Q2 2022 | 112 | $122.1M |
| Q1 2022 | 116 | $167.8M |
| Q4 2021 | 106 | $269.2M |
| Q3 2021 | 105 | $360.2M |
| Q2 2021 | 101 | $389.0M |
| Q1 2021 | 74 | $225.2M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Vistagen Therapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Millennium Management LLC | 1,240,285 | $1.54M | 0.00% | +1,229,705+11,622.9% | Added |
| Ghost Tree Capital, LLC | 1,315,154 | $1.63M | 0.81% | −684,846−34.2% | Reduced |
| Norges Bank | 1,318,800 | $1.64M | 0.00% | +1,318,800 | New |
| Northern Trust Corp | 1,635,003 | $2.03M | 0.00% | −319,283−16.3% | Reduced |
| Geode Capital Management, LLC | 3,227,765 | $4.00M | 0.00% | +155,104+5.0% | Added |
| State Street Corp | 3,609,840 | $4.48M | 0.00% | −4,990,394−58.0% | Reduced |
| Nicholas Investment Partners, LP | 4,570,387 | $5.67M | 0.40% | +282,310+6.6% | Added |
| Sphera Funds Management Ltd. | 4,951,423 | $6.14M | 1.03% | +926,485+23.0% | Added |
| Vanguard Group Inc | 9,268,067 | $11.5M | 0.00% | +3,5380.0% | Added |
| Franklin Resources Inc | 9,940,537 | $12.3M | 0.00% | −177,462−1.8% | Reduced |
| Commodore Capital LP | 10,097,229 | $12.5M | 2.80% | +1,632,230+19.3% | Added |
| BlackRock Inc. | 11,732,424 | $14.5M | 0.00% | −161,769−1.4% | Reduced |
| Acuta Capital Partners, LLC | 11,736,283 | $14.6M | 6.92% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 12,909,283 | $16.0M | 0.26% | 00.0% | Unchanged |
| VR Adviser, LLC | 16,047,286 | $19.9M | 3.22% | 00.0% | Unchanged |
| NEA Management Company, LLC | 16,302,596 | $20.2M | 0.65% | 00.0% | Unchanged |
| Rafferty Asset Management, LLC | 0 | $0 | 0.00% | −490,295−100.0% | Sold out |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −424,181−100.0% | Sold out |
| Bulltick Wealth Management, LLC | 0 | $0 | 0.00% | −223,340−100.0% | Sold out |
| Rock Creek Group, LP | 0 | $0 | 0.00% | −161,589−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −102,847−100.0% | Sold out |
| E Fund Management Co., Ltd. | 0 | $0 | 0.00% | −16,206−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −14,800−100.0% | Sold out |
| Zacks Investment Management | 0 | $0 | 0.00% | −12,000−100.0% | Sold out |
| Confluence Wealth Services, Inc. | 0 | $0 | 0.00% | −1,700−100.0% | Sold out |